Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

31-10-2018 | Brief Report

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study

Auteurs: Adi Aran, Hanoch Cassuto, Asael Lubotzky, Nadia Wattad, Esther Hazan

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 3/2019

Abstract

Anecdotal evidence of successful cannabis treatment in autism spectrum disorder (ASD) are accumulating but clinical studies are lacking. This retrospective study assessed tolerability and efficacy of cannabidiol-rich cannabis, in 60 children with ASD and severe behavioral problems (age = 11.8 ± 3.5, range 5.0–17.5; 77% low functioning; 83% boys). Efficacy was assessed using the Caregiver Global Impression of Change scale. Adverse events included sleep disturbances (14%) irritability (9%) and loss of appetite (9%). One girl who used higher tetrahydrocannabinol had a transient serious psychotic event which required treatment with an antipsychotic. Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients. This preliminary study supports feasibility of CBD-based cannabis trials in children with ASD.

vorige artikel Brief Report: Descriptive Analysis of Law Enforcement Officers’ Experiences with and Knowledge of Autism

volgende artikel Brief Report: Regional Variations in Characteristics of ASD Hospitalizations in the U.S.

Alleen toegankelijk voor geautoriseerde gebruikers

Adler, B. A., Wink, L. K., Early, M., Shaffer, R., Minshawi, N., McDougle, C. J., et al. (2015). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism, 19(1), 102–106. https://doi.org/10.1177/1362361314524641.PubMedCrossRef

Ballaban-Gil, K., & Tuchman, R. (2000). Epilepsy and epileptiform EEG: Association with autism and language disorders. Mental Retardation and Developmental Disabilities Research Reviews, 6(4), 300–308, https://doi.org/10.1002/1098-2779(2000)6:4%3C300::aid-mrdd9%3E3.0.co;2-r.PubMedCrossRef

Campos, A. C., Fogaca, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., et al. (2017). Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Frontiers in Pharmacology, 8, 269. https://doi.org/10.3389/fphar.2017.00269.PubMedPubMedCentralCrossRef

Chakrabarti, B., & Baron-Cohen, S. (2011). Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces. Molecular Autism, 2(1), 10. https://doi.org/10.1186/2040-2392-2-10.PubMedPubMedCentralCrossRef

Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., et al. (2017). Trial of Cannabidiol for drug-resistant seizures in the dravet syndrome. The New England Journal of Medicine, 376(21), 2011–2020. https://doi.org/10.1056/NEJMoa1611618.PubMedCrossRef

Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., et al. (2018). Effect of Cannabidiol on drop seizures in the lennox-gastaut syndrome. The New England Journal of Medicine, 378(20), 1888–1897. https://doi.org/10.1056/NEJMoa1714631.PubMedCrossRef

Gururajan, A., Taylor, D. A., & Malone, D. T. (2012). Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. The Journal of Psychopharmacology, 26(10), 1317–1332. https://doi.org/10.1177/0269881112441865.PubMedCrossRef

Hofer, J., Hoffmann, F., & Bachmann, C. (2017). Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: A systematic review. Autism, 21(4), 387–402. https://doi.org/10.1177/1362361316646559.PubMedCrossRef

Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences of the United States of America, 114(42), 11229–11234. https://doi.org/10.1073/pnas.1711351114.PubMedPubMedCentralCrossRef

Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., et al. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9, 18. https://doi.org/10.1186/s13229-018-0203-y.PubMedPubMedCentralCrossRef

King, B. H., Dukes, K., Donnelly, C. L., Sikich, L., McCracken, J. T., Scahill, L., et al. (2013). Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial. JAMA Pediatrics, 167(11), 1045–1052. https://doi.org/10.1001/jamapediatrics.2013.2698.PubMedPubMedCentralCrossRef

Lee, B. H., Smith, T., & Paciorkowski, A. R. (2015). Autism spectrum disorder and epilepsy: Disorders with a shared biology. Epilepsy & Behavior, 47, 191–201. https://doi.org/10.1016/j.yebeh.2015.03.017.CrossRef

Maskey, M., Warnell, F., Parr, J. R., Le Couteur, A., & McConachie, H. (2013). Emotional and behavioural problems in children with autism spectrum disorder. Journal of Autism and Developmental Disorders, 43(4), 851–859. https://doi.org/10.1007/s10803-012-1622-9.PubMedCrossRef

Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy & Behavior, 70(Pt B), 319–327. https://doi.org/10.1016/j.yebeh.2016.11.006.CrossRef

Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 391(10125), 1085–1096. https://doi.org/10.1016/s0140-6736(18)30136-3.PubMedCrossRef

Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18091916.PubMedPubMedCentralCrossRef

Titel: Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study
Auteurs: Adi Aran
Hanoch Cassuto
Asael Lubotzky
Nadia Wattad
Esther Hazan
Publicatiedatum: 31-10-2018
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 3/2019
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-018-3808-2

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 3/2019

Healthy Mothers Healthy Families Workshop Intervention: A Preliminary Investigation of Healthy Lifestyle Changes for Mothers of a Child with a Disability

Autism Scientists’ Reflections on the Opportunities and Challenges of Public Engagement: A Qualitative Analysis

Life After an Autism Spectrum Disorder Diagnosis: A Comparison of Stress and Coping Profiles of African American and Euro-American Caregivers

Thinking Ahead: Incremental Language Processing is Associated with Receptive Language Abilities in Preschoolers with Autism Spectrum Disorder

Should Heritage Languages be Incorporated into Interventions for Bilingual Individuals with Neurodevelopmental Disorders? A Systematic Review

Outpatient Psychotherapy for Adults with High-Functioning Autism Spectrum Condition: Utilization, Treatment Satisfaction, and Preferred Modifications